San Francisco, CA, United States of America

Daniel A Erlanson

USPTO Granted Patents = 17 (Patent Applications = 13)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 115(Granted Patents)

Company Filing History:

14 out of 63

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

patents

6. 1 out of 36

Millenium Pharmaceuticals, Inc.

patents

7. 1 out of 1

Cannot Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11572374 - N-cyano-7-azanorbornane derivatives and uses thereof (2023-02-07),

2. 11535660 - Modulators of G-protein coupled receptors (2022-12-27),

3. 11053226 - KRAS G12C inhibitors and methods of using the same (2021-07-06),

4. 10577374 - Bruton's tyrosine kinase inhibitors (2020-03-03),

5. 10107798 - Methods of chemotype evolution (2018-10-23),

6. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

7. 9873693 - Methods of treatment using pyridinonyl PDK1 inhibitors (2018-01-23),

8. 9790229 - Bruton's tyrosine kinase inhibitors (2017-10-17),

9. 9546165 - Heterocyclic compounds useful as PDK1 inhibitors (2017-01-17),

10. 9249146 - Bruton'S tyrosine kinase inhibitors (2016-02-02),

11. 9029359 - Heteroaryl Btk inhibitors (2015-05-12),

12. 8785440 - Bruton's tyrosine kinase inhibitors (2014-07-22),

13. 8778977 - Pyridinonyl PDK1 inhibitors (2014-07-15),

14. 7214487 - Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates (2007-05-08),

15. 6919178 - Extended tethering approach for rapid identification of ligands (2005-07-19),

Title: The Innovative Contributions of Daniel A Erlanson

Introduction

Daniel A Erlanson, located in San Francisco, CA, is a prominent inventor known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 17 patents, Erlanson's work has paved the way for innovative therapeutic solutions.

Latest Patents

Two of Erlanson's latest patents demonstrate his expertise in medicinal chemistry. The first, titled "N-cyano-7-azanorbornane derivatives and uses thereof," focuses on a compound that provides various pharmaceutical applications. This invention outlines a method for manufacturing the compounds and emphasizes their therapeutic uses.

The second patent, "Modulators of G-protein coupled receptors," features chemical entities capable of modulating the activities of glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR). These advancements are crucial for developing treatments for conditions where modulation of these receptors can significantly benefit patients’ underlying pathologies.

Career Highlights

Throughout his career, Daniel A Erlanson has made impactful strides in pharmaceutical research. He has held positions at several esteemed companies, including Sunesis Pharmaceuticals and Biogen MA Inc. His work consistently reflects a commitment to addressing complex medical challenges through innovative solutions.

Collaborations

Erlanson's journey has seen fruitful collaborations with notable individuals in his field. Among his colleagues are Gnanasambandam Kumaravel and Daniel M Scott, who have contributed to the success of various projects alongside Erlanson.

Conclusion

Daniel A Erlanson exemplifies the spirit of innovation in the pharmaceutical industry. His 17 patents highlight a commitment to advancing medical science, with particular focus on new therapeutic methods and compounds that aim to improve patient outcomes. As a leading inventor, Erlanson continues to inspire the next generation of scientists and researchers.

This text is generated by artificial intelligence and may not be accurate.